Press Release-Alphamab Oncology

English 中文简体中文繁体

English 中文简体中文繁体

NEWS Press Release Media Report

Year:

Select

Press Release

01 May 2025

A Pivotal Phase II/III Clinical Study of Anti-HER2 Bispecific Antibody KN026 Have Met the Primary Endpoint of PFS at Interim Analysis KN026 in combination with chemotherapy as second-line or above treatment of HER2-positive GC (including GEJ)
30 April 2025

Alphamab Oncology Presented Preclinical Data on Two Novel Bispecific ADCs at the 2025 AACR Annual Meeting JSKN021 and JSKN022 exhibit significant differentiating features in preclinical study
26 March 2025

Alphamab Oncology Reports Full Year 2024 Financial Results and Business Highlights Full year 2024 financial results and business highlights, reached profitability for the first time on an annual basis
18 March 2025

Anti-HER2 Biparatopic ADC JSKN003 Has Been Granted Breakthrough-Therapy Designation for the Treatment of PROC not restricted to HER2 expression levels.
27 February 2025

First Patient Dosed in a Phase III Clinical Study of Anti-HER2 Biparatopic ADC JSKN003 for the Treatment of HER2-positive Breast Cancer The expedited progression of this study is anticipated to offer a treatment option with improved efficacy and safety for this patient population, further improving prognosis and quality of life.
13 February 2025

Alphamab Oncology Announces the First Patient Dosed in a Phase III Clinical Study for Ovarian Cancer of Anti-HER2 Bispecific ADC JSKN003 The study aims to compare the efficacy and safety of JSKN003 versus investigator-selected chemotherapy in this patient population.
06 February 2025

Anti-HER2 Bispecific ADC JSKN003 Received Approval to Initiate a Phase III Clinical Study for the Treatment of HER2-positive Breast Cancer This marks the third Phase III clinical study initiated for JSKN003, following the trials in HER2 low-expressing breast cancer and platinum-resistant ovarian cancer.
14 Janurary 2025

Alphamab Oncology Announces the First Patient Dosed in a Phase I/II Clinical Study of Anti-HER2 Bispecific ADC Subcutaneous Co-formulation JSKN033 This study has previously been included in the "Pilot Program for Optimizing the Review and Approval of Clinical Trials for Innovative Drugs"
27 December 2024

Alphamab Oncology Announced Anti-HER2 Bispecific ADC JSKN003 Received Approval from CDE to Initiate a Phase III Clinical Study for Ovarian Cancer for the all-comer population with platinum-resistant recurrent epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer who have received 1-4 lines of prior treatment
26 December 2024

IND Application for a Phase I/II Clinical Study of Anti-HER2 Bispecific ADC Subcutaneous Co-formulation JSKN033 was Approved This study has previously been included in the "Pilot Program for Optimizing the Review and Approval of Clinical Trials for Innovative Drugs".